Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Swiss pharma giant Roche Holding AG's RHHBY first-quarter 2026 results were affected by currency headwinds. Sales totaled $18 ...

Ironwood Pharmaceuticals, Inc. , a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the ...

Can weight-loss drugs like semaglutide prevent Alzheimer's? New research reveals GLP-1 drugs reduce amyloid and tau proteins ...

People on GLP-1s may struggle to get enough protein, fiber, and other nutrients. Can frozen dinners labeled ‘GLP-1 Friendly’ ...

People taking GLP-1s had reduced risk for atrial fibrillation, regardless of whether they lost weight or how much they lost, ...

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid ...

Retatrutide shows big weight loss potential but isn’t FDA-approved. Here’s what to know about its safety and legal risks.

(Corrects typo in first bulletpoint, changes Struggilng to Struggling) By Heather Schlitz CHICAGO, April 23 (Reuters) - Aaron ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...